Setareh Akhavan; Nadereh Behtash; Mohsen Esfandbod; Mitra Moddares Gilani; Azam-Sadat Mousavi; Shahrzad Sheikh Hasani
Volume 2, Issue 4 , November and December 2017, , Pages 1-4
Abstract
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women. Primary surgery, followed by adjuvant chemotherapy is the basis of treatment for this disease. A standard treatment includes primary surgery and if possible optimal debulking surgery (tumor residue of <; 1 cm), followed ...
Read More
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women. Primary surgery, followed by adjuvant chemotherapy is the basis of treatment for this disease. A standard treatment includes primary surgery and if possible optimal debulking surgery (tumor residue of <; 1 cm), followed by a chemotherapy; paclitaxel carboplatin is the standard regimen in ovarian cancer. Given that the main method of spreading this disease is in the peritoneal cavity, the systemic chemotherapy brings about numerous complications; moreover, as the method of prescribing a drug inside the peritoneum causes a high drug concentration in the peritoneal cavity, conducting an intraperitoneal chemotherapy has been examined clinically. In cases of ovarian cancer recurrence, performing a secondary cytoreductive surgery, in addition to hyperthermic intraperitoneal chemotherapy (HIPEC), has led to a good survival among patients. Currently, studies are ongoing to better explain the effects of this treatment method compared to previous methods.
Setare Nasiri; Shahrzad Sheikh Hasani; Mohammad Rahim Vakili; Fateme Nilli
Volume 2, Issue 3 , September and October 2017
Abstract
Introduction: Synovial sarcoma of the ovary is a very rare tumor reported only once in the past. It is the second softest tissue mass after rhabdomyosarcoma in adults but its usual site is extremities not ovary.
Case Presentation: Here we describe a 53-year-old woman with primary synovial sarcoma of ...
Read More
Introduction: Synovial sarcoma of the ovary is a very rare tumor reported only once in the past. It is the second softest tissue mass after rhabdomyosarcoma in adults but its usual site is extremities not ovary.
Case Presentation: Here we describe a 53-year-old woman with primary synovial sarcoma of the ovary with insufficient treatment and lung metastasis of the tumor.
Conclusions: Because of harmlessness symptoms, it is usually missed and correct treatment is delayed. When facing this type of tumor, referring to well-equipped centers with experienced surgeons in this field is recommended for sufficient treatment and best results.
Setare Nasiri; Azamosadat Mousavi; Shahrzad Sheikh Hasani; Mohammad Rahim Rahim Vakili; Mitra Modarres Gilani; Setare Akhavan; Monire Mirzaei
Volume 2, Issue 3 , September and October 2017
Abstract
Introduction: The incidence of vulvar cancer is nearly 5% of all gynecologic malignancies and almost 95% of vulvar cancers are squamous cell carcinoma (SCC). Recurrence is possible in 4 ways: local, regional, pelvic, and distant. In a cohort of 391 patients with vulvar SCC, distant metastasis was reported ...
Read More
Introduction: The incidence of vulvar cancer is nearly 5% of all gynecologic malignancies and almost 95% of vulvar cancers are squamous cell carcinoma (SCC). Recurrence is possible in 4 ways: local, regional, pelvic, and distant. In a cohort of 391 patients with vulvar SCC, distant metastasis was reported 5% .The common sites of distant metastasis are pelvic nodes, lung, and liver. Both skin and bone metastasis are rare in vulvar SCC.
Case Presentation: The current report presented a 58-year-old female with the diagnosis of vulvar SCC. She was the 11th cutaneous metastasis, 13th bone metastasis, and the 1st case with simultaneous bone and skin metastasis reported in the last 60 years.
Conclusions: It is necessary to consider any lesion on the vulve, especially in menopause females, and it should be the low threshold for biopsy to avoid delay in detection. After completion of selective treatment, the exact follow-up should be considered to discover metastases.
Setare Nasiri; Shahrzad Sheikh Hasani; Azamosadat Mousavi; Mitra Modarres Gilani; Setare Akhavan; Mohammad Rahim Vakili
Volume 1, Issue 3 , November and December 2016
Abstract
Introduction: One of the rare ovarian neoplasms is sclerosing stromal tumor (SST). The most common age at presentation of sclerosing stromal tumor is the second and third decades of life. Usually this tumor presents with menstrual irregularity and pelvic pain as reported previously. Surgery is mandatory ...
Read More
Introduction: One of the rare ovarian neoplasms is sclerosing stromal tumor (SST). The most common age at presentation of sclerosing stromal tumor is the second and third decades of life. Usually this tumor presents with menstrual irregularity and pelvic pain as reported previously. Surgery is mandatory for diagnosis because there is not any distinctive feature to diagnose by imaging techniques.
Case Presentation: Our case in this report is a 26-year-old woman presented with pelvic pain. We conducted routine laboratory tests and checked ovarian mass tumor markers preoperatively. Due to her normal hormonal status in physical examination, we did not request more hormonal laboratory tests. However on imaging, we did not suspect benign tumor. Doppler sonography showed low resistance flow in peripheral and center of the mass. Right ovarian mass was resected and diagnosed as ovarian stromal tumor compatible with sclerosing stromal tumor. Unexpectedly at operation, we encountered severe hemorrhage from peritoneal surface so that conservative management such as packing and suturing or cauterization was not helpful. Finally, argon coagulation stopped bleeding. All coagulation laboratory tests requested by a hematologist were normal.
Conclusions: In conclusion, we believe that vascular endothelial growth factor (VEGF) production of tumor is responsible for massive bleeding.
Setare Nasiri; Shahrzad Sheikh Hasani; Azamosadat Mousavi; Mitra Modarres Gilani; Setare Akhavan; Mohammad Rahim Rahim Vakili
Volume 1, Issue 3 , November and December 2016
Abstract
Introduction: Mesonephric adenocarcinoma of uterine cervix is a rare variant of primary endocervical adenocarcinoma and a few cases have been reported previously. In fact in non-metastatic adenocarcinoma of the cervix, less than 5% possess mesonephric type. Because of the low incidence of mesonephric ...
Read More
Introduction: Mesonephric adenocarcinoma of uterine cervix is a rare variant of primary endocervical adenocarcinoma and a few cases have been reported previously. In fact in non-metastatic adenocarcinoma of the cervix, less than 5% possess mesonephric type. Because of the low incidence of mesonephric adenocarcinoma, various methods have been proposed for treatment of mesonephric adenocarcinoma. Nevertheless, there is no unity in treatment approaches.
Case Presentation: Here, we present a 45-year woman who had bloody discharge for 6 months period. Hormonal profile such as thyroid stimulating hormon (TSH) and prolactin was normal and all imaging studies showed a cervical fibroma as a mass. Abdominal hysterectomy -bilateral salpingectomy was performed. After pathologic report as a mesonephric adenocarcinoma, she received radiation and then she was candidate for bilateral oophorectomy.
Conclusions: Because of the diversity and an unusual appearance of mesonephric adenocarcinoma with aproblematic case of cervical mass, it is very important to consider mesonephric adenocarcinoma as a type of diagnosis. Numerous differential diagnoses should be considered for management of this type of carcinoma. In order to make a diagnosis, deep biopsy of infiltrative mass of uterine cervix, is mandatory.
